

URB602 Inhibits Monoacylglycerol Lipase and Selectively Blocks 2-Arachidonoylglycerol Degradation in Intact Brain Slices

Alvin R. King,¹ Andrea Duranti,³ Andrea Tontini,³ Silvia Rivara,⁴ Anja Rosengarth,² Jason R. Clapper,¹ Giuseppe Astarita,¹ Jennifer A. Geaga,¹ Hartmut Luecke,² Marco Mor,⁴ Giorgio Tarzia,³ and Daniele Piomelli^{1,*}

¹Department of Pharmacology

²Department of Molecular Biology and Biochemistry

University of California, Irvine, Irvine, CA, 92697, USA

³Institute of Medicinal Chemistry, University of Urbino "Carlo Bo," Urbino, 61029, Italy

⁴Pharmaceutical Department, University of Parma, Parma, 43100, Italy

*Correspondence: piomelli@uci.edu

DOI 10.1016/j.chembiol.2007.10.017

SUMMARY

The *N*-aryl carbamate URB602 (biphenyl-3-ylcarbamic acid cyclohexyl ester) is an inhibitor of monoacylglycerol lipase (MGL), a serine hydrolase involved in the biological deactivation of the endocannabinoid 2-arachidonoyl-*sn*-glycerol (2-AG). Here, we investigated the mechanism by which URB602 inhibits purified recombinant rat MGL by using a combination of biochemical and structure-activity relationship (SAR) approaches. We found that URB602 weakly inhibits recombinant MGL ($IC_{50} = 223 \pm 63 \mu M$) through a rapid and noncompetitive mechanism. Dialysis experiments and SAR analyses suggest that URB602 acts through a partially reversible mechanism rather than by irreversible carbamoylation of MGL. Finally, URB602 (100 μM) elevates 2-AG levels in hippocampal slice cultures without affecting levels of other endocannabinoid-related substances. Thus, URB602 may provide a useful tool by which to investigate the physiological roles of 2-AG and explore the potential interest of MGL as a therapeutic target.

INTRODUCTION

2-Arachidonoyl-*sn*-glycerol (2-AG) is a major monoacylglycerol (MAG) species present in mammalian tissues and, along with anandamide, is an endogenous ligand for cannabinoid (CB) receptors [1, 2]. These lipid messengers, called endocannabinoids, are produced on demand through cleavage of membrane phospholipid precursors and are implicated in a variety of short-range signaling processes [2, 3]. In the central nervous system (CNS), the endocannabinoids activate CB₁ receptors on presynaptic terminals to regulate calcium- and potassium-chan-

nel activity, as well as neurotransmitter release [4]. These neuromodulatory effects have a wide range of functional consequences. In particular, their proposed involvement in the regulation of pain, appetite, and mood has significant therapeutic potential and highlights the importance of understanding the mechanisms by which endocannabinoids are produced and eliminated [5].

The biological deactivation of 2-AG and anandamide is thought to require a two-step process involving carrier-mediated transport into cells and subsequent intracellular hydrolysis [6–8]. 2-AG is hydrolyzed by two or more monoacylglycerol lipase (MGL) enzymes [9, 10], one of which has been molecularly cloned [11, 12], whereas anandamide is hydrolyzed by fatty-acid amide hydrolase (FAAH) [13] and *N*-acyl ethanolamine acid amidase (NAAA) [14].

The cloned MGL is a 303 amino acid serine hydrolase that resides in the cell cytosol and cleaves MAGs into fatty acid and glycerol [11, 12]. Three lines of evidence suggest that this enzyme plays a key role in the physiological deactivation of 2-AG in the CNS. First, MGL is expressed at high levels in the rodent brain [12], where it is predominantly found in presynaptic nerve terminals of both excitatory and inhibitory neurons [15]. Second, virally induced overexpression of MGL dampens *N*-methyl-D-aspartate (NMDA)-dependent accumulation of 2-AG in rat cortical neurons [12], whereas RNAi-mediated silencing of constitutive MGL expression increases 2-AG levels in HeLa cells [16]. Finally, pharmacological blockade of intracellular MGL activity by two structurally unrelated inhibitors, URB602 (biphenyl-3-ylcarbamic acid cyclohexyl ester) and methylarachidonylfluorophosphonate (MAFP), elevates 2-AG levels and enhances 2-AG-mediated signaling in neurons [17, 18]. For example, microinjections of URB602 or MAFP in the periaqueductal gray matter of the midbrain selectively increase 2-AG levels, but not anandamide levels, and enhance CB₁ receptor-mediated stress-induced analgesia in rats [17]. Furthermore, administration of URB602 or MAFP prolongs endocannabinoid-mediated changes in synaptic strength in acutely dissected rat hippocampal slices [18]. Even further, administration of URB602 in rodents has been shown to produce




Figure 1. Expression of Recombinant MGL

(A) Coomassie staining (left) and western blot (right) analyses of purified recombinant MGL expressed in *E. coli*.

(B) Time course of oleic acid (OA) production from 2-oleoyl-*sn*-glycerol (2-OG) in the presence of purified MGL (10 ng). Results are the average of two experiments, each performed in duplicate.

anti-inflammatory and antinociceptive effects that are selectively blocked by CB₂ receptor antagonists [19, 20]. Thus, URB602 and MAFP may be used to investigate the physiological roles of 2-AG and the pharmacological potential of MGL inhibition, provided that appropriate precautions are taken to control for the limitations of these agents. In particular, questions that remain to be addressed concern (i) the molecular identity of the MAG-hydrolyzing enzyme(s) targeted by URB602 and MAFP; and (ii) the mechanisms by which URB602 and MAFP inhibit this enzyme(s). Answering these questions may help resolve current inconsistencies in the literature, such as a recent study reporting that URB602 exerts little or no inhibitory effect on 2-AG hydrolysis in broken-cell preparations of brain tissue [21]. Therefore, in the present study, we have sought to (i) reexamine the inhibitory effects of URB602 on MGL activity, by using both a purified recombinant MGL and intact brain neurons; and (ii) investigate the mechanism by which URB602 inhibits cloned MGL, by using an approach that combines kinetic, dialysis, and structure-activity relationship (SAR) analyses.

RESULTS AND DISCUSSION

Expression of Recombinant MGL

We overexpressed recombinant rat MGL in *E. coli* and purified it by affinity chromatography. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analyses of the purified protein, followed by Coomassie blue staining or immunoblotting, revealed a single band that closely matched the calculated molecular weight of histidine-tagged cloned rat brain MGL (35.7 kD) (Figure 1A). As expected, recombinant MGL hydrolyzed the MAG substrate 2-oleoylglycerol (2-OG) in a time-dependent and protein concentration-dependent manner (Figure 1B; data not shown).

Inhibition of Recombinant MGL

Figure 2A shows the concentration-dependent inhibition of purified recombinant MGL by URB602 ($IC_{50} = 223 \pm 63 \mu M$, $n = 4$) and by the broad-spectrum lipase inhibitor MAFP ($35 \pm 13 nM$, $n = 3$) under standard conditions (10 min, 37°C) [22–24]. In some experiments, we measured the ability of URB602 to inhibit MGL activity in assays

of 2.5 min duration, and we obtained similar results across experiments ($IC_{50} = 185 \pm 13 \mu M$, $n = 3$). Figure 2A also illustrates the effect of the MGL inhibitor *N*-arachidonyl-maleimide (NAM) [25] ($IC_{50} = 46 \pm 7 nM$, $n = 3$). Figure 2B depicts the effects of URB602, MAFP, and NAM on recombinant MGL overexpressed in HeLa cells (IC_{50} values: URB602, $81 \pm 13 \mu M$; MAFP, $23 \pm 0.1 nM$; NAM, $41 \pm 19 nM$; $n = 3$ –4). Notably, URB602 was significantly more potent at inhibiting nonpurified MGL expressed in HeLa cells than purified MGL expressed in *E. coli* ($p < 0.05$, unpaired Student's *t* test), suggesting that posttranslational modifications or differences in the enzyme assay environment may alter the inhibitory potency of this compound. An alternate interpretation is that HeLa cells express another 2-OG-hydrolyzing enzyme that has higher sensitivity to URB602 than the cloned MGL.

Inhibition of Cerebellar MGL

The ability of URB602, MAFP, and NAM to inhibit MGL activity was further investigated by using cerebellar membranes. A previous study with this preparation reported no effect of URB602 on 2-AG hydrolysis [21]. We found, however, that both URB602 and NAM inhibited MAG hydrolysis in cerebellar membranes in a concentration-dependent manner (Figure 2C). Interestingly, neither agent achieved complete inhibition, even when tested at concentrations that were maximally effective on cloned MGL. By contrast, MAFP virtually eliminated 2-OG hydrolysis, suggesting that cerebellar membranes contain multiple MGL activities, and that URB602 and NAM only affect a subset of such activities.

Kinetic Analyses of MGL Inhibition

To explore the mechanism by which URB602 inhibits MGL, we measured recombinant MGL activity at various substrate concentrations, in the absence or presence of URB602 (0.3 and 1 mM) (Figure 3A). Incubation with URB602 resulted in an increase in the Michaelis-Menten constant (K_M) and a decrease in the maximal velocity (V_{max}) of the MGL reaction (Table 1). This result suggests that URB602 inhibits MGL activity in a noncompetitive manner. In particular, the reciprocal effect of URB602 on K_M and V_{max} indicates that the inhibitor may bind with greater affinity to the free enzyme than the enzyme-substrate complex [26].




Figure 2. Inhibition of MGL Activity by Various Agents

(A and B) Effects of URB602 (circles, $n = 4$), MAFP (triangles, $n = 3$), or NAM (squares, $n = 3$) on either (A) purified MGL expressed in *E. coli* or (B) MGL expressed in HeLa cells. Results are expressed as mean \pm SEM; each assay is performed in duplicate.

(C) Inhibition of MGL activity in cerebellar membranes by URB602, MAFP, or NAM. Results are expressed as mean \pm SEM ($n = 3$); each assay is performed in triplicate. * $p < 0.05$, ** $p < 0.01$, ANOVA, followed by Dunnett's test; # $p < 0.05$, unpaired Student's *t* test.

Time Course of MGL Inhibition

We next examined the time dependence of MGL inhibition by URB602 (0.3 mM). Maximal percent inhibition occurred within 2 min of URB602 addition, and this level remained unchanged for up to 1 hr (Figures 3B and 3C). To determine whether URB602 itself may be hydrolyzed by MGL during the incubation period, we measured URB602 concentrations by using liquid chromatography/mass spectrometry (LC/MS). Although a small decrease in URB602 levels was seen immediately after initiating the incubation, possibly due to absorption to glassware, no further change occurred for the rest of the experiment (Figure 3C). The

results indicate that URB602 (i) inhibits MGL in a time-independent manner, and (ii) does not serve as a substrate for MGL.

Reversibility of MGL Inhibition

The *O*-aryl carbamate URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) inhibits FAAH activity by an irreversible mechanism that likely involves carbamylation of an active-site serine residue of the enzyme [27, 28]. To test whether URB602, an *N*-aryl carbamate, also inhibits MGL irreversibly, we incubated the purified enzyme in the presence of URB602 (30 and 100 μ M) and then subjected the incubation mixture to extensive dialysis (24 hr, 0°C–4°C). Dialysis partially reversed the inhibition of MGL activity by URB602 (Figure 3D), suggesting that this agent inhibits MGL through a mechanism that is at least partially reversible.

Structure-Activity Relationship Studies

We also investigated the chemical requirements for MGL inhibition by URB602 (Table 2). A series of modifications were made to the two substituents on the carbamate moiety, focusing on the importance of the substituent aromaticity (3a), the ester moiety (3j and 3l), *N*-alkylation (3o), the shape of the *N*-biphenyl-3-yl group (3b, 3d–3g, and 3k), the role of the *O*-cyclohexyl group (3c), and the potential of the *O*-substituent to serve as a leaving group by mimicking the glycerol fragment of 2-AG (3h, 3i, 3m, and 3n). Finally, as our kinetic and dialysis results challenged the role of the carbamate group in MGL inhibition, we replaced this group with various isosteric moieties (4a, 5, and 6). Only one compound in this focused series, the noncarbamate derivative 4a, was found to be more effective than URB602 at inhibiting MGL activity ($IC_{50} = 115 \mu$ M) (Table 2). Because compound 4a retains a high steric similarity with URB602, but has a much lower tendency to give a covalent bond with a nucleophilic serine, this result supports the possibility that URB602 and 4a are not active site-directed MGL inhibitors.

Recently, a carbamate, SPB 01403 (*n*-butylcarbamic acid 4-[4,5-dihydrothiazol-2-yl]phenyl ester), that inhibits MAG-hydrolyzing activity in rat cerebellar membranes with an IC_{50} value of 31 μ M has been reported [29] (Figure 4). Although it belongs to the same chemical class as URB602, this compound has a carbamate group with a different electronic environment, due to the presence of an aromatic *O*-substituent with an electron-withdrawing group in a conjugated position. Although the mechanism of this inhibitor has not been elucidated, it may differ from that which is reported here for URB602, given the large difference in reactivity between their carbamate fragments.

Effect of URB602 on 2-AG and Anandamide Levels in Neurons

Previous studies indicate that URB602 protects endogenous 2-AG from degradation in intact brain tissue [17, 18]. Thus, as an additional test of the ability of URB602 to selectively inhibit MGL, we examined the effects of this




Figure 3. Characterization of the Mechanism of MGL Inhibition by URB602

(A) Michaelis-Menten analysis of the MGL reaction in the presence of vehicle (DMSO, 1%) (circles, $n = 4$), 0.3 mM URB602 (triangles, $n = 3$), or 1 mM URB602 (squares, $n = 3$). Results are expressed as mean \pm SEM.

(B) Time course of the MGL reaction in the presence of 1% DMSO (circles) or 0.3 mM URB602 (triangles). Results are expressed as mean \pm SEM ($n = 5$).

(C) Changes in MGL inhibition over time, replotted as the percent of maximal inhibition (closed squares), are shown. Changes in URB602 concentration over time, plotted as the percent of initial concentration (open triangles), are also shown. Results are expressed as mean \pm SEM ($n = 3$).

(D) Effects of URB602 on MGL activity before (open bars) and after (closed bars) dialysis (24 hr, 0°C–4°C). Results are expressed as mean \pm SEM ($n = 6$). ** $p < 0.01$, *** $p < 0.001$, unpaired Student's t test.

agent on 2-AG content in rat hippocampal slices in primary cultures. As shown in Figure 5A, treatment with URB602 (100 μ M, 25 min) produced a significant elevation in 2-AG levels compared to vehicle (0.1% DMSO in Dulbecco's modified Eagle's medium) ($n = 5$). In the same slices, the levels of the FAAH substrates anandamide (Figure 5B) and palmitoylethanolamide (PEA) (Figure 5C) were not affected. These findings suggest that URB602 inhibits the degradation of 2-AG without affecting that of other endocannabinoid-related substances.

SIGNIFICANCE

In the present study, we show that the *N*-aryl carbamate URB602 inhibits purified recombinant rat brain MGL and increases 2-AG levels in intact brain neurons. We further show that MGL inhibition by URB602 occurs through a rapid, noncompetitive, and partially reversible mechanism, suggesting that URB602—unlike *O*-aryl carbamate FAAH inhibitors such as URB597 [27]—does not covalently modify MGL. SAR studies confirm this possibility, pointing to substituted ureas as a starting point for the discovery of novel MGL inhibitors. Such agents are important for three

Table 1. Michaelis-Menten Constant and Maximal Rate of Reaction for Purified Recombinant MGL Expressed in *E. coli*

URB602 (mM)	0	0.3	1
K_M (μ M)	16.92 ± 3.188	27.05 ± 2.045	32.11 ± 1.083
V_{max} (pmol/min/ng)	120.6 ± 12.44	106.1 ± 2.750	82.68 ± 6.273

Michaelis-Menten constant, K_M ; maximal rate of reaction, V_{max} . Data are represented as mean \pm SEM (average of three experiments performed in triplicate).

reasons. First, they may help uncover specific functions served by 2-AG in endocannabinoid signaling. Second, they may provide an experimental tool by which to validate MGL as a therapeutic target. Last, they may serve as chemical scaffolds for the development of drug-like MGL inhibitors with potential applications in the treatment of stress-related disorders [17], pain [19], and inflammation [20]. Thus, despite its limited potency, URB602 remains a useful tool by which to investigate the roles of 2-AG and validate MGL as a pharmacological target.

EXPERIMENTAL PROCEDURES

Chemicals

MAFP and NAM were purchased from Cayman Chemical (Ann Arbor, MI), 2-OG was purchased from Sigma-Aldrich (St. Louis, MO), and 2-[3 H]-AG was purchased from Cayman Chemical; [3 H]-anandamide and [3 H]-palmitoylethanolamide were synthesized in the lab [30].

Chemistry

All chemicals were purchased from Sigma-Aldrich in the highest quality commercially available. Solvents were RP grade, unless otherwise indicated. Chromatographic separations were performed on open silica-gel columns by flash chromatography (Kieselgel 60, 0.040–0.063 mm, Merck). The weight ratio between the material loaded in the column and the stationary phase was about 1:50. Thin-layer chromatography (TLC) analyses were performed on precoated silica-gel sheets (Kieselgel 60 F₂₅₄, Merck). Melting points were determined on a Büchi SMP-510 capillary melting-point apparatus. EI-MS spectra (70 eV) were recorded with a Fisons Trio 1000 spectrometer; only molecular ions (M^+) and base peaks are given. 1 H-NMR spectra were recorded on an AVANCE Bruker 200 spectrometer; chemical shifts are reported in δ scale and were measured by using the central peak of the solvent. Infrared spectra (IR) were obtained on a Shimadzu FT-8300, or a Nicolet Avatar, spectrometer; absorbances are reported in ν (cm^{-1}).

Synthetic Procedures

URB602 was synthesized as previously reported [17]. Carbamates **3a–3l** were prepared by addition of an appropriate amine (**1**) and an alcohol (**2**) to carbonyldiimidazole (CDI); all reagents are commercially

Table 2. IC₅₀ Values for Inhibition of Purified Recombinant MGL by Various URB602 Derivatives




















Compound	Structure	IC ₅₀ (μM)
URB602		223 ± 63
3a		>300
3b		>300
3c		>300
3d		>300
3e		>300
3f		>300
3g		>300
3h		>300
3i		>300
3j		>300
3k		>300
3l		243 (n = 2)
3 m		>300
3n		>300
3o		>300

Table 2. Continued

Compound	Structure	IC ₅₀ (μM)
4a		115 (n = 2)
5		>300
6		>300

Data are expressed as mean ± SEM (n = 3).

available, except 5-hydroxy-2,2-dimethyl-1,3-dioxane (**2a**), which was prepared according to literature [31], biphenyl-3-ylamine (**1a**) [32], 5-phenyl-1-pentylamine (**1c**) [33], and substituted anilines **1d–1f**. **1d** and **1e** were obtained by a Suzuki coupling of 3-bromoaniline and the appropriate boronic acid. **1f** resulted from coupling of potassium 3-phenylphenolate and 3-bromoaniline at high temperature in the presence of copper powder. *N*-Methylcarbamate, **3o**, was obtained by alkylation of URB602 in basic conditions. Acid hydrolysis of acetal **3i** afforded **3n**. Urea, **4a**, was synthesized by the addition of **1c** and cyclohexylamine to CDI. Amide **5** was prepared from the corresponding acid via acyl chloride; thiocarbamate **6** was prepared by the addition of **1c** and cyclohexanethiol to CDI.

N-Aryl-*O*-alkylcarbamates, **3a–3l**

CDI (0.648 g, 4 mmol; **3e**: 0.324 g, 2 mmol) and triethylamine (TEA) (0.71 ml, 5 mmol) were added to a stirred solution of the suitable amine (**1**) (2 mmol) in dry CH₃CN (22 ml). After the reactants were refluxed for 4 hr (**2 hr**: **3h**, **3i**, **3k**, **3l**; **8 hr**: **3g**; **20 hr**: **3b**, **3j**), the appropriate alcohol, **2** (2 mmol), was added, and the mixture reacted for the appropriate amount of time (**3f**: 1 hr; **3c–3e**, **3j**: 2 hr; **3h**, **3i**, **3k**: 4 hr; **3g**: 8 hr; **3l**: 9 hr; **3a**, **3b**: 20 hr). In some cases, an additional amount of alcohol (**3d**, **3e**: 1 mmol; **3a**: 6 mmol) and heating (**3d**, **3e**: 0.5 hr; **3a**: 24 hr) were necessary. The mixture was cooled and concentrated. Purification of the residue by column chromatography (cyclohexane:EtOAc, 9:1: **3a**, **3d**, **3f**, **3j**; 85:15: **3c**; 8:2: **3b**, **3e**, **3g**, **3l**; 7:3; then EtOAc:MeOH, 98:2: **3h**; petroleum ether:EtOAc, 75:25: **3i**) and, in the case of solids, recrystallization gave the desired compounds.

(5-Phenylpentyl)carbamic Acid Cyclohexyl Ester, **3a**

3a appeared as a colorless oil. Yield: 26% (0.150 g). MS (EI): 289 (M⁺); 207 (100). ¹H-NMR (CDCl₃): 1.28–1.93 (m, 16H); 2.62 (t, 2H); 3.16 (t, 2H); 4.64 (br s, 2H); 7.16–7.32 (m, 5H) ppm. IR (Neat): 3344, 3083, 3064, 3021, 2932, 2847, 1689.

Phenylcarbamic Acid Cyclohexyl Ester, **3b**

3b appeared as white crystals. Yield: 91% (0.399 g). Mp: 81°C–83°C (petroleum ether; sealed capillary tube) (lit. 81°C–82°C). MS (EI): 219 (M⁺); 93 (100). ¹H-NMR and IR are according to the literature [34].

Biphenyl-3-ylcarbamic Acid 5-Phenylpentyl Ester, **3c**

3c appeared as white tufts. Yield: 96% (0.689 g). Mp: 92°C–93°C (EtOH; sealed capillary tube). MS (EI): 359 (M⁺); 91 (100). ¹H-NMR (CDCl₃): 1.45–1.80 (m, 6H); 2.65 (t, 2H); 4.19 (t, 2H); 6.66 (br s, 1H); 7.17–7.66 (m, 14H) ppm. IR (Nujol): 3316, 1703.

(3'-Methylbiphenyl-3-yl)carbamic Acid Cyclohexyl Ester, **3d**

3d appeared as a yellow oil. Yield: 35% (0.216 g). MS (EI): 309 (M⁺); 183 (100). ¹H-NMR (CDCl₃): 1.26–1.94 (m, 10H); 2.42 (s, 3H); 4.78 (m, 1H); 6.60 (d, 1H); 7.15–7.67 (m, 8H) ppm. IR (Neat): 3321, 3055, 3022, 2925, 2849, 1730, 1698.

(3'-Trifluoromethylbiphenyl-3-yl)carbamic Acid Cyclohexyl Ester, **3e**

3e appeared as white needles. Yield: 56% (0.406 g). Mp: 72°C–74°C (petroleum ether). MS (EI): 363 (M⁺); 281 (100). ¹H-NMR (CDCl₃): 1.26–1.99 (m, 10H); 4.78 (m, 1H); 6.67 (br s, 1H); 7.30–7.83 (m, 8H) ppm. IR (Nujol): 3321, 1692.




Figure 4. Structure of the MGL Inhibitor SPB 01403

(3-[Biphenyl-3-yloxy]phenyl)carbamic Acid Cyclohexyl Ester, 3f

3f appeared as a pale-yellow oil. Yield: 13% (0.101 g). MS (EI): 387 (M^+); 287 (100). $^1\text{H-NMR}$ (CDCl_3): 1.27–1.90 (m, 10H); 4.74 (m, 1H); 6.56 (br s, 1H); 6.73–7.59 (m, 13H) ppm. IR (Neat): 3397, 3316, 1714.

Biphenyl-2-ylcarbamic Acid Cyclohexyl Ester, 3g

3g appeared as a brown oil. Yield: 97% (0.572 g). MS (EI): 295 (M^+); 169 (100). $^1\text{H-NMR}$ (CDCl_3): 1.27–1.91 (m, 10H); 4.73 (m, 1H); 6.59 (s, 1H); 7.08–7.55 (m, 8H); 8.14 (d, 1H) ppm. IR (Nujol): 3421, 1728.

Biphenyl-3-ylcarbamic Acid 2,3-Dihydroxypropyl Ester, 3h

3h appeared as a white solid. Yield: 21% (0.121 g). Mp: 130°C–132°C (EtOAc/petroleum ether; sealed capillary tube). MS (EI): 287 (M^+); 195 (100). $^1\text{H-NMR}$ (d_6 -acetone): 3.58 (d, 2H); 3.88 (m, 2H); 4.20 (m, 3H); 7.29–7.66 (m, 8H); 7.91 (s, 1H); 8.80 (s, 1H) ppm. IR (Neat): 3362, 1790, 1714.

Biphenyl-3-ylcarbamic Acid 2,2-Dimethyl[1,3]dioxan-5-yl Ester, 3i

3i appeared as white crystals. Yield: 64% (0.419 g). MS (EI): 327 (M^+); 195 (100). Mp: 116°C–117°C [(i-Pr) $_2$ O]. $^1\text{H-NMR}$ (CDCl_3): 1.49 (d, 6H); 3.92–4.24 (m, 4H); 4.74 (m, 1H); 6.95 (s, 1H); 7.29–7.65 (m, 9H) ppm. IR (Nujol): 3348, 1725.

Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester, 3j

3j appeared as pearly crystals. Yield: 18% (0.131 g). Mp: 166°C–169°C (EtOH; sealed capillary tube). MS (EI): 365 (M^+); 115 (100). $^1\text{H-NMR}$ (CDCl_3): 7.07 (br s, 1H); 7.18–7.24 (m, 1H); 7.33–7.51 (m, 12H); 7.59–7.64 (m, 4H); 7.78 (br s, 1H) ppm. IR (Nujol): 3337, 1704.

Biphenyl-4-ylcarbamic Acid Cyclohexyl Ester, 3k

3k appeared as white crystals. Yield: 37% (0.218 g). Mp: 142°C–143°C (EtOH). MS (EI): 295 (M^+); 213 (100). $^1\text{H-NMR}$ (CDCl_3): 1.26–1.95 (m, 10H); 4.78 (m, 1H); 6.65 (s, 1H); 7.32–7.60 (m, 9H) ppm. IR (Nujol): 3376, 3338, 1698.

Biphenyl-3-ylcarbamic Acid Phenyl Ester, 3l

3l appeared as pearly crystals. Yield: 15% (0.088 g). Mp: 84°C–85°C (EtOH). MS (EI): 289 (M^+); 94 (100). $^1\text{H-NMR}$ (CDCl_3): 7.08 (br s, 1H); 7.25 (m, 3H); 7.42 (m, 8H); 7.62 (m, 2H); 7.77 (br s, 1H) ppm. IR (Nujol): 3293, 1710.

(3'-Methylbiphenyl-3-yl)carbamic Acid 2-Hydroxy-1-hydroxymethylethyl Ester, 3m

CDI (1.754 g, 10.83 mmol) and TEA (2.5 ml, 34.5 mmol) were added to a solution of 3'-methylbiphenyl-3-ylamine (**1d**) (1.03 g, 5.63 mmol) in dry CH_3CN (80 ml). The mixture was refluxed for 2 hr, **2a** was then added (0.740 g, 5.61 mmol), and the mixture was again refluxed (4 hr). The solvent was evaporated, and purification of the residue by column chromatography (8:2 cyclohexane:EtOAc) gave a sample (0.800 g) of (3'-methylbiphenyl-3-yl)carbamic acid 2,2-dimethyl[1,3]dioxan-5-yl ester (MS [EI]: 341 [M^+], 209 [100]) and a product whose R_f corresponds to that of **1d** (approximate ratio of 1:1 by TLC). This mixture was added to a 1:50 mixture of 37% HCl:THF (20 ml) and was allowed to react under stirring at room temperature overnight. The solvent was evaporated, and purification of the residue by column chromatography (EtOAc) gave **3m** as a colorless, fruity-smelling oil that solidified in the freezer and, after recrystallization, turned into a white solid. Yield: 27% (0.450 g). Mp: 100°C–103°C (EtOAc/petroleum ether; sealed capillary tube). MS (EI): 301 (M^+); 209 (100). $^1\text{H-NMR}$ (d_6 -acetone): 2.40 (s, 3H); 3.76 (m, 4H); 3.95 (m, 2H); 4.87 (m, 1H); 7.57 (m, 1H); 7.16–7.46 (m, 6H); 7.93 (t, 1H); 8.70 (s, 1H) ppm. IR (Neat): 3342, 2926, 1710.1. (3'-meth-

ylbiphenyl-3-yl)-3-(3'-methylbiphenyl-4-yl)urea (**4b**) (0.230 g; Mp: 214°C–217°C [EtOH]; MS [EI]: 392 [M^+], 209 [100]; $^1\text{H-NMR}$ (CDCl_3): 2.09 [s, 6H]; 7.17–7.99 [m, 14H]; 7.89 [m, 2H]; 8.28 [s, 2H]. IR [Nujol]: 3287, 1710) was also isolated as a side product of the reaction.

Biphenyl-3-ylcarbamic Acid 2-Hydroxy-1-hydroxymethylethyl Ester, 3n

3i (0.170 g; 0.52 mmol) was added to a 1:50 mixture of 37% HCl:THF (8 ml), and the solution reacted under stirring at room temperature for 3 hr. The mixture was quenched with 2N NaHCO_3 and extracted with EtOAc. The organic phase was dried and concentrated. Purification of the residue by column chromatography (200:5 EtOAc:MeOH) and recrystallization gave **3n** as colorless crystals. Yield: 40% (0.060 g). Mp: 100°C–102°C (EtOAc/petroleum ether; sealed capillary tube). MS (EI): 287 (M^+); 195 (100). $^1\text{H-NMR}$ (d_6 -acetone): 3.75 (m, 4H); 3.97 (br s, 2H); 4.86 (m, 1H); 7.29–7.67 (m, 8H); 7.94 (s, 1H); 8.72 (s, 1H) ppm. IR (Neat): 3289, 1779, 1692.

Biphenyl-3-ylmethylcarbamic Acid Cyclohexyl Ester, 3o

Cs_2CO_3 (0.420 g, 1.29 mmol) and tetrabutylammonium iodide (0.480 g, 1.29 mmol) were added to a solution of URB602 (0.127 g, 0.43 mmol) in dry DMF (5 ml). The mixture was stirred at room temperature for 30 min. CH_3I (0.183 g, 0.8 ml, 1.29 mmol) was added, and the mixture was allowed to react further (8 hr). H_2O was then added, and the mixture was extracted with EtOAc. The organic phase was washed with brine, dried, and concentrated. Purification of the residue by column chromatography (7:3 cyclohexane:EtOAc) afforded **3o** as a colorless oil. Yield: 49% (0.065 g). MS (EI): 309 (M^+); 152 (100). $^1\text{H-NMR}$ (CDCl_3): 1.26–1.84 (m, 10H); 3.36 (s, 3H); 4.77 (m, 1H); 7.32–7.60 (m, 9H) ppm. IR (Neat): 3061, 3033, 2930, 2849, 1698.

1-(Biphenyl-3-yl)-3-cyclohexyl Urea, 4a

TEA (0.253 g, 0.35 ml, 2.5 mmol) was added to a solution of **1c** (0.169 g, 2 mmol) and CDI (0.324 g, 2 mmol) in dry CH_3CN (11 ml), and the mixture was stirred under reflux for 2 hr. Then, cyclohexylamine (0.099 g, 2.5 mmol, 0.105 ml) was added, and the mixture was stirred under reflux for 4 hr and was concentrated. Purification of the residue by column chromatography (8:2 cyclohexane:EtOAc) and recrystallization gave **4a** as a white solid. Yield: 51% (0.300 g). Mp: 179°C–183°C (EtOH). MS (EI): 294 (M^+); 169 (100). $^1\text{H-NMR}$ (d_6 -acetone): 0.90–1.72 (m, 10H); 3.38 (m, 1H); 6.29 (m, 1H); 7.03–7.36 (m, 8H); 7.55 (s, 1H); 7.86 (br s, 1H) ppm. IR (Nujol): 3332, 1714.

N-Biphenyl-3-yl-2-cyclohexylacetamide, 5

Oxalyl chloride (0.508 g, 0.35 ml, 4 mmol) was added under nitrogen to a cooled (0°C) solution of cyclohexylacetic acid (0.142 g, 0.14 ml, 1 mmol) in dry THF (3.3 ml). The mixture was stirred at room temperature for 2 hr and concentrated, and the residue was dissolved in CH_2Cl_2 (3.3 ml). TEA (0.283 g, 0.39 ml, 2.8 mmol) and **1c** (0.220 g, 1.3 mmol) in a minimal amount of CH_2Cl_2 were added, the mixture was stirred for 20 hr, and the solvent was concentrated. The purification of the residue by column chromatography (75:25 cyclohexane:EtOAc) and recrystallization gave **5** as a white, fluffy solid. Yield: 48% (0.140 g). Mp: 108°C–109°C (EtOH). MS (EI): 293 (M^+); 169 (100). $^1\text{H-NMR}$ (CDCl_3): 0.93–1.97 (m, 11H); 2.25 (d, 2H); 7.30–7.62 (m, 9H); 7.79 (s, 1H) ppm. IR (Nujol): 3283, 1649.

Biphenyl-3-ylthiocarbamic Acid S-Cyclohexyl Ester, 6

CDI (0.648 g, 4 mmol) and TEA (0.515 g, 0.71 ml, 5.1 mmol) were added to a solution of **1d** (0.372 g, 2.2 mmol) in dry CH_3CN (2 ml). After refluxing for 4 hr, cyclohexanethiol (0.232 g, 0.25 ml, 2 mmol) was added. The mixture was refluxed for 3 hr, cooled, and evaporated. Purification of the residue by column chromatography (9:1 cyclohexane:EtOAc) and recrystallization gave **6** as pale-yellow crystals. Yield: 70% (0.435 g). Mp: 108°C–111°C (EtOH, sealed capillary tube). MS (EI): 311 (M^+); 195 (100). $^1\text{H-NMR}$ (d_6 -DMSO): 1.22–2.09 (m, 10H); 3.57 (m, 1H); 7.09 (br s, 1H); 7.25–7.71 (m, 9H) ppm. IR (Nujol): 3294, 3137, 3082, 1643.

3-(3'-Substituted)phenylanilines, 1d and 1e

$\text{Pd}(\text{PPh}_3)_4$ (0.282 mg, 0.244 mmol), a solution of Na_2CO_3 (3.990 g, 37.6 mmol) in H_2O (18 ml), and a solution of the suitable 3-substituted phenylboronic acid (6.72 mmol) in EtOH (18 ml) were added to a stirred solution of 3-bromoaniline (1.032 g, 6 mmol) in toluene (42 ml). The mixture was vigorously stirred under reflux for 1 hr, cooled, added to




Figure 5. Effects of URB602 on Endocannabinoid Levels in Rat Brain Slices

(A and B) Effects of URB602 (100 μ M) or vehicle (0.1% DMSO in DMEM) on (A) 2-AG levels, (B) anandamide levels, and (C) PEA levels in rat organotypic hippocampal slices in culture. Results are expressed as mean \pm SEM ($n = 4-5$). ** $p < 0.01$, ns = not significant, unpaired Student's t test.

water, and extracted with EtOAc. The combined organic layers were dried and concentrated. Purification of the residue by column chromatography (8:2 cyclohexane:EtOAc) and, in the case of **1e**, recrystallization gave **1d** and **1e**.

3'-Methylbiphenyl-3-ylamine, **1d**

1d appeared as an opaque, yellow oil that solidifies in the freezer. Yield: 56% (0.614 g). Mp: 45.5°C–46.5°C (trituration with petroleum ether). MS (EI): 183 (M^+ , 100). $^1\text{H-NMR}$ (CDCl_3): 2.43 (s, 3H); 3.72 (br s, 2H); 6.70 (m, 1H); 6.93 (t, 1H); 7.01 (m, 1H); 7.15–7.40 (m, 5H) ppm. IR (Neat): 3457, 3376, 3213, 3028, 2919, 2843, 1622, 1600.

3'-Trifluoromethylbiphenyl-3-ylamine, **1e**

1e appeared as colorless needles. Yield: 43% (0.610 g). Mp: 40°C–42°C (petroleum ether). MS (EI): 237 (M^+ , 100). $^1\text{H-NMR}$ (CDCl_3): 3.83 (br s, 2H); 6.74 (m, 1H); 6.97 (m, 2H); 7.27 (m, 1H); 7.56 (m, 2H); 7.78 (m, 2H) ppm. IR (Nujol): 3446, 3332, 3196, 1622.

3-(Biphenyl-3-yloxy)phenylamine, **1f**

3-Bromoaniline (1.672 g, 1.16 mmol, 10.65 mmol) and copper (0.630 g, 10 mmol) were added to a cooled (0°C) solution of potassium 3-phenylphenolate (obtained by adding 3-phenylphenol [1.81 g, 10.65 mmol] to a solution of potassium [0.410 g, 10.65 mmol] in dry MeOH [40 ml], stirring the mixture for 0.5 hr at room temperature, evaporating the solvent, and drying the residue). The mixture was stirred at 160°C–170°C for 12 hr, cooled, and concentrated. Purification of the residue by column chromatography (8:2 cyclohexane:EtOAc) gave **1f** as a brown oil. Yield: 23% (0.642 g). MS (EI): 261 (M^+); 170 (100). $^1\text{H-NMR}$ (CDCl_3): 3.70 (br s, 2H); 6.44 (m, 2H); 6.99–7.61 (m, 11H) ppm. IR (Neat): 3468, 3381, 3218, 3066, 3033, 2925, 2849, 1736.

MGL Cloning

Rat MGL cDNA was cloned out of the pBluescript-SK vector by using the following primers: 5'-CGCGGCAGCCATATGCTGAGCAAGTTCA CC-3' (forward primer) and 5'-AGCAGCCGGATCCTCTCAGGGTAG ACACCTAG-3' (reverse primer). These primers introduced a BamHI and an NdeI endonuclease restriction site at the 5' and 3' end, respectively, of the cDNA. Platinum Pfx DNA polymerase (Invitrogen, Carlsbad, CA) was used to run the polymerase chain reaction (PCR), followed by a BamHI/NdeI double digest of the PCR product and the pET15b vector (Novagen, La Jolla, CA) containing an N-terminal histidine tag. The vector and the PCR product were ligated by using T4 DNA ligase (Promega, Madison, WI) after the dephosphorylation of the pET15b vector DNA. The ligation setup was transformed into DH5 α *E. coli* cells and were plated on a Luria Broth agar plate containing 50 μ g/ml ampicillin. Ten colonies were selected, and their plasmid DNAs were purified according to the QIAGEN plasmid DNA miniprep Kit protocol (QIAGEN, Valencia, CA). Restriction digest analysis resulted in four positive clones, which were subjected to DNA sequencing, confirming the correct sequence.

MGL Expression and Purification

Clone 2 was expressed in Rosetta 2(DE3)pLysS *E. coli* cells (Novagen) at 37°C by using 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG). This clone was used for all subsequent protein expression experiments. 4 L LB plus 50 μ g/ml ampicillin was inoculated with 40 ml over-

night culture of Rosetta 2(DE3)pLysS cells transformed with pET15b/MGL grown in LB plus 50 μ g/ml ampicillin. Cells were grown at 37°C until the optical density (OD) at 600 nm reached 0.8. At this point, addition of IPTG to a final concentration of 1 mM induced MGL overexpression. After 4 hr, the cells were harvested by centrifugation at 6,000 \times g for 15 min, and the bacterial pellet was resuspended in 100 ml lysis buffer (50 mM HEPES [pH 7.4], 300 mM NaCl, 10 mM MgCl_2 , 3 mM β -mercaptoethanol, 0.5 mM benzamidine, 10 μ M E-64, and 10 μ g/ml aprotinin). The cells were lysed by using a French press, and the cell lysate was centrifuged at 3,000 \times g for 1 hr at 4°C to separate the membrane fraction from the cell debris. The supernatant (membrane fraction) was then subjected to another centrifugation at 35,000 \times g for 1 hr at 4°C. The pellet was resuspended in 50 mM HEPES (pH 7.4), 300 mM NaCl, 3 mM β -mercaptoethanol, 1% Triton X-100; stirred for \sim 30 min, and centrifuged again at 5,000 \times g for 1 hr at 4°C. The supernatant was loaded onto a TALON column (Clontech, Mountain View, CA) equilibrated with 50 mM HEPES (pH 7.4), 300 mM NaCl, 3 mM β -mercaptoethanol, 0.1% Triton X-100 (buffer A). The column was washed with five volumes of buffer A, and the protein was subsequently eluted from the column by using a step gradient of imidazole ranging from 10 to 200 mM imidazole in buffer A (five column volumes each). The protein eluted at \sim 75 mM imidazole.

Protein Analysis

The protein concentration of the purified MGL was determined by Coomassie blue staining by using fatty acid-free bovine serum albumin (BSA) (Sigma-Aldrich) as a standard. SDS-PAGE and western blot were performed as previously described [35], by using 4%–20% Tris-glycine gels (Invitrogen). For western blot, proteins were transferred onto an Immun-Blot PVDF membrane (BioRad, Hercules, CA) by using a Semiphor Transphor Unit (Amersham, Piscataway, NJ) and were incubated with a rabbit MGL antibody [12]. Immunoreactive bands were visualized by using the ECL-Plus Kit (Amersham).

Cerebellar Membrane Preparation

Male Wistar rats were anesthetized by halothane and decapitated, and cerebella (minus the brainstem) were dissected and placed immediately in 10 volumes of ice-cold 20 mM Tris (pH 7.5) with 0.32 M sucrose. Tissue was homogenized and Potterized, then centrifuged at 1,000 \times g for 10 min at 4°C. The supernatant was removed and subjected to further centrifugation at 27,000 \times g for 30 min at 4°C. The pellet was resuspended in 50 mM Tris (pH 7.5). The protein concentration was measured by Bradford Assay.

Measurement of MGL Activity

The final reaction consisted of 0.445 ml assay buffer (50 mM Tris-HCl [pH 8.0], 0.5 mg/ml BSA, fatty acid-free) containing either 10 ng purified *E. coli* MGL, 200 ng nonpurified HeLa MGL [12], or 50 μ g cerebellar membranes, 50 μ l 2-OG (prepared in assay buffer, 10 μ M final), and 5 μ l URB602, MAFF, or NAM (prepared in DMSO), for a final total reaction volume of 0.5 ml. The final concentration of vehicle (1% DMSO) had no effect on MGL activity. After a 10 min incubation at 37°C, reactions were stopped by the addition of 3 ml chloroform:methanol (2:1, vol:vol),

containing heptadecanoic acid (5 nmol) (Nu-chek Prep, Elysian, MN) as an internal standard. After centrifugation at 2,000 × g at 4°C for 10 min, the organic layers were collected and dried under N₂. The residues were suspended in 50 µl chloroform:methanol (1:3, vol:vol) and analyzed by LC/MS. We used a reverse-phase XDB Eclipse C18 column (50 × 4.6 mm i.d., 1.8 µm, Agilent Technologies, Wilmington, DE) eluted with a linear gradient from 90% to 100% of A in B for 2.5 min at a flow rate of 1.5 ml/min with the column temperature at 40°C. Mobile phase A consisted of methanol containing 0.25% acetic acid and 5 mM ammonium acetate; mobile phase B consisted of water containing 0.25% acetic acid and 5 mM ammonium acetate. ESI was in the negative mode, capillary voltage was set at 4 kV, and the fragmentor voltage was 100 V. N₂ was used as a drying gas at a flow rate of 13 l/min and a temperature of 350°C. Nebulizer pressure was set at 60 psi. For quantification purposes, we monitored the [M-H]⁻ ions of *m/z* = 281.3 for oleic acid and *m/z* = 269 for heptadecanoic acid.

Measurement of URB602

Samples containing either URB602 (300 µM), MGL (1.4 pM), or both URB602 and MGL were incubated at 37°C for 30 min in assay buffer. At various time points, the reaction was stopped with an equal volume of ice-cold methanol and was directly analyzed in positive ionization mode by LC/MS. We used a SB-CN column (150 × 2.1 mm i.d., 5 µm, Agilent) eluted with a linear gradient of methanol in water containing 0.25% acetic acid and 5 mM ammonium acetate (from 60% to 100% of methanol in 8 min) at a flow rate of 0.5 ml/min with the column temperature at 50°C. Capillary voltage was set at 4 kV, and fragmentor voltage was 100 V. Nebulizer pressure was set at 60 psi. N₂ was used as a drying gas at a flow rate of 13 l/min and a temperature of 350°C. ESI was in the positive mode, and a full scan spectrum was acquired from *m/z* = 100 to 600. Extracted ion chromatograms were used to quantify URB602 ([M+H]⁺, *m/z* = 296).

Hippocampal Slice Cultures

Hippocampal organotypic slice cultures were prepared from Wistar rats as previously described [36]. Briefly, postnatal day-9 rats were sacrificed by cryoanesthesia, hippocampi were dissected from 0.4 mm coronal slices prepared by using a vibratome, and three hippocampi per well were incubated in Neurobasal medium on Millicell culture inserts (Millipore, Billerica, MA). Slices were maintained for 8 days at 37°C with 5% CO₂ before treatment with either URB602 (100 µM) or vehicle (0.1% DMSO in DMEM) for 25 min at 37°C. Reactions were stopped by a wash with ice-cold PBS, followed by fixation with 4% paraformaldehyde for 30 min at room temperature. Slices were then extracted in 1 ml ice-cold methanol:chloroform:water (1:1:2, vol:vol:vol) containing 500 pmol 2-[²H₆]-AG and 10 pmol each of [²H₄]-anandamide and [²H₄]-palmitylethanolamide, added as internal standards. Organic phases were recovered, evaporated under N₂, reconstituted in 50 µl chloroform:methanol (1:3, vol:vol), and analyzed by LC/MS as previously described [18].

ACKNOWLEDGMENTS

The authors would like to thank Faizy Ahmed (Agilent Technologies) for his advice on LC/MS-related experiments. This work was supported by the National Institute on Drug Abuse (R01 DA-012447), University of California Discovery (02-10337), the National Institutes of Health Training Program in Cellular and Molecular Neuroscience (T32NS007444-7), and the Italian Ministry of University and Research (2005032713_002).

Received: September 4, 2007

Revised: October 17, 2007

Accepted: October 31, 2007

Published: December 26, 2007

REFERENCES

1. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., and Waku, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem. Biophys. Res. Commun.* 215, 89–97.
2. Stella, N., Schweitzer, P., and Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. *Nature* 388, 773–778.
3. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C., and Piomelli, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature* 372, 686–691.
4. Freund, T.F., Katona, I., and Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic signaling. *Physiol. Rev.* 83, 1017–1066.
5. Piomelli, D. (2005). The endocannabinoid system: a drug discovery perspective. *Curr. Opin. Investig. Drugs* 6, 672–679.
6. Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A., and Piomelli, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. *Science* 277, 1094–1097.
7. Hillard, C.J., Edgemond, W.S., Jarrahan, A., and Campbell, W.B. (1997). Accumulation of *N*-arachidonylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. *J. Neurochem.* 69, 631–638.
8. Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. *Nat. Rev. Neurosci.* 4, 873–884.
9. Goparaju, S.K., Ueda, N., Taniguchi, K., and Yamamoto, S. (1999). Enzymes of porcine brain hydrolyzing 2-arachidonolglycerol, an endogenous ligand of cannabinoid receptors. *Biochem. Pharmacol.* 57, 417–423.
10. Muccioli, G.G., Xu, C., Odah, E., Cudaback, E., Cisneros, J.A., Lambert, D.M., López Rodríguez, M.L., Bajjalieh, S., and Stella, N. (2007). Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. *J. Neurosci.* 27, 2883–2889.
11. Karlsson, M., Contreras, J.A., Hellman, U., Tornqvist, H., and Holm, C. (1997). cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. *J. Biol. Chem.* 272, 27218–27223.
12. Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L., Kathuria, S., and Piomelli, D. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc. Natl. Acad. Sci. USA* 99, 10819–10824.
13. Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., and Gilula, N.B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature* 384, 83–87.
14. Tsuboi, K., Sun, Y.X., Okamoto, Y., Araki, N., Tonai, T., and Ueda, N. (2005). Molecular characterization of *N*-acylethanolamine-hydrolyzing acid amidase, a novel member of the cholesteryl glyceride hydrolase family with structural and functional similarity to acid ceramidase. *J. Biol. Chem.* 280, 11082–11092.
15. Gulyas, A.I., Cravatt, B.F., Bracey, M.H., Dinh, T.P., Piomelli, D., Boschia, F., and Freund, T.F. (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. *Eur. J. Neurosci.* 20, 441–458.
16. Dinh, T.P., Kathuria, S., and Piomelli, D. (2004). RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. *Mol. Pharmacol.* 66, 1260–1264.

17. Hohmann, A.G., Suplita, R.L., Bolton, N.M., Neely, M.H., Fegley, D., Mangieri, R., Krey, J.F., Walker, M., Holmes, P.V., Crystal, J.D., et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. *Nature* 435, 1108–1112.
18. Makara, J.K., Mor, M., Fegley, D., Szabo, S.I., Kathuria, S., Astarita, G., Duranti, A., Tontini, A., Tarzia, G., Rivara, S., et al. (2005). Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. *Nat. Neurosci.* 8, 1139–1141.
19. Guindon, J., Desroches, J., and Beaulieu, P. (2007). The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB₂ receptors. *Br. J. Pharmacol.* 150, 693–701.
20. Comelli, F., Giannoni, G., Bettoni, I., Colleoni, M., and Costa, B. (2007). The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. *Br. J. Pharmacol.* 152, 787–794.
21. Saario, S.M., Palomäki, V., Lehtonen, M., Nevalainen, T., Järvinen, T., and Laitinen, J.T. (2006). URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. *Chem. Biol.* 13, 811–814.
22. Dinh, T.P., Freund, T.F., and Piomelli, D. (2002). A role for monoacylglycerol lipase in 2-arachidonoylglycerol inactivation. *Chem. Phys. Lipids* 121, 149–158.
23. Deutsch, D.G., Omeir, R., Arreaza, G., Salehani, D., Prestwich, G.D., Huang, Z., and Howlett, A. (1997). Methyl arachidonoyl fluorophosphate: a potent irreversible inhibitor of anandamide amidase. *Biochem. Pharmacol.* 53, 255–260.
24. Lio, Y.C., Reynolds, L.J., Balsinde, J., and Dennis, E.A. (1996). Irreversible inhibition of Ca²⁺-independent phospholipase A₂ by methyl arachidonoyl fluorophosphate. *Biochim. Biophys. Acta* 1302, 55–60.
25. Saario, S.M., Salo, O.M.H., Nevalainen, T., Poso, A., Laitinen, J.T., Järvinen, T., and Niemi, R. (2005). Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. *Chem. Biol.* 12, 649–656.
26. Copeland, R.A. (2005). Reversible modes of inhibitor interactions with enzymes. In *Evaluation of Enzyme Inhibitors in Drug Discovery*, R.A. Copeland, ed. (Hoboken, NJ: John Wiley and Sons, Inc.), pp. 56–63.
27. Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. *Nat. Med.* 9, 76–81.
28. Alexander, J.P., and Cravatt, B.F. (2005). Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. *Chem. Biol.* 12, 1179–1187.
29. Saario, S.M., Poso, A., Juvonen, R.O., Järvinen, T., and Salo-Ahen, O.M.H. (2006). Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. *J. Med. Chem.* 49, 4650–4656.
30. Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., and Piomelli, D. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. *J. Pharmacol. Exp. Ther.* 313, 352–358.
31. Forbes, D.C., Ene, D.G., and Doyle, M.P. (1998). Stereoselective synthesis of substituted 5-hydroxy-1,3-dioxanes. *Synthesis* 6, 879–882.
32. Leung, W.-Y., Mao, F., Haugland, R.P., and Kalubert, D.H. (1996). Lipophilic sulfophenylcarbocyanine dyes: synthesis of a new class of fluorescent cell membrane probes. *Bioorg. Med. Chem. Lett.* 6, 1479–1482.
33. Marcinek, A., Platz, M.S., Chan, S.Y., Floresca, R., Rajagopalan, K., Golinski, M., and Watt, D. (1994). Unusually long lifetimes of the singlet nitrenes derived from 4-azido-2,3,5,6-tetrafluorobenzamides. *J. Phys. Chem.* 98, 412–419.
34. Leardini, R., and Zanardi, G. (1982). A new and facile synthesis of alkyl *N*-arylcabamates. *Synthesis* 3, 225–227.
35. Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). Transfer of proteins from SDS-polyacrylamide gels to solid supports: immunological detection of immobilized proteins (western blotting). In *Molecular Cloning: A Laboratory Manual*, Second Edition, N. Ford, ed. (Plainview, NY: Cold Spring Harbor Laboratory Press), pp. 18.60–18.75.
36. Stoppini, L., Buchs, P.A., and Muller, D. (1991). A simple method for organotypic cultures of nervous tissue. *J. Neurosci. Methods* 37, 173–182.